GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » BrainsWay Ltd (NAS:BWAY) » Definitions » Cyclically Adjusted Price-to-FCF

BrainsWay (BrainsWay) Cyclically Adjusted Price-to-FCF : (As of Jun. 11, 2024)


View and export this data going back to 2019. Start your Free Trial

What is BrainsWay Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


BrainsWay Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for BrainsWay's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BrainsWay Cyclically Adjusted Price-to-FCF Chart

BrainsWay Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

BrainsWay Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of BrainsWay's Cyclically Adjusted Price-to-FCF

For the Medical Devices subindustry, BrainsWay's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BrainsWay's Cyclically Adjusted Price-to-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, BrainsWay's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where BrainsWay's Cyclically Adjusted Price-to-FCF falls into.



BrainsWay Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

BrainsWay's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, BrainsWay's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.148/131.7762*131.7762
=0.148

Current CPI (Mar. 2024) = 131.7762.

BrainsWay Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -0.135 100.560 -0.177
201409 -0.242 100.428 -0.318
201412 -0.166 99.070 -0.221
201503 -0.376 99.621 -0.497
201506 -0.274 100.684 -0.359
201509 -0.166 100.392 -0.218
201512 -0.118 99.792 -0.156
201603 -0.047 100.470 -0.062
201606 -0.156 101.688 -0.202
201609 -0.033 101.861 -0.043
201612 -0.165 101.863 -0.213
201703 -0.246 102.862 -0.315
201706 -0.136 103.349 -0.173
201709 -0.101 104.136 -0.128
201712 -0.094 104.011 -0.119
201803 -0.127 105.290 -0.159
201806 -0.296 106.317 -0.367
201809 -0.106 106.507 -0.131
201812 -0.210 105.998 -0.261
201903 -0.150 107.251 -0.184
201906 -0.435 108.070 -0.530
201909 -0.297 108.329 -0.361
201912 -0.143 108.420 -0.174
202003 -0.307 108.902 -0.371
202006 -0.037 108.767 -0.045
202009 -0.146 109.815 -0.175
202012 0.157 109.897 0.188
202103 -0.051 111.754 -0.060
202106 -0.146 114.631 -0.168
202109 -0.039 115.734 -0.044
202112 0.140 117.630 0.157
202203 -0.150 121.301 -0.163
202206 -0.132 125.017 -0.139
202209 -0.132 125.227 -0.139
202212 -0.133 125.222 -0.140
202303 -0.204 127.348 -0.211
202306 -0.030 128.729 -0.031
202309 0.051 129.860 0.052
202312 0.124 129.419 0.126
202403 0.148 131.776 0.148

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


BrainsWay  (NAS:BWAY) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


BrainsWay Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of BrainsWay's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


BrainsWay (BrainsWay) Business Description

Traded in Other Exchanges
Address
19 Hartum Street, 3rd Floor, Bynet Building, Har Hotzvim, Jerusalem, ISR, 9777518
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.